Drugs / AZD0466
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05205161 | Jul 2022 → Aug 2023 | non-Hodgkin lymphoma | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT04865419 | Jun 2021 → Aug 2023 | hematopoietic and lymphoid cell neoplasm | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT04214093 | Dec 2019 → Jun 2021 | plasma cell myeloma | AstraZeneca | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD0466 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05205161 ↗ |
| Route | Intravenous | “administered IV” NCT04214093 ↗ |